MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.92

23 Feb
2024

-0.030

OPEN

$0.95

-3.16%

HIGH

$0.96

73,127

LOW

$0.90

TARGET
$1.60 73.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MVP: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx - 6.7 - 0.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/03 - ex-div 2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-6.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx32.3 M
Book Value Per Share xxxxxxxxxxxxxxx94.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-16.5 M
Net Profit Margin xxxxxxxxxxxxxxx-17.35 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-8.09 %
Return on Invested Capital xxxxxxxxxxxxxxx-7.83 %
Return on Assets xxxxxxxxxxxxxxx-5.32 %
Return on Equity xxxxxxxxxxxxxxx-8.09 %
Return on Total Capital xxxxxxxxxxxxxxx-28.16 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-18.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx9 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx25 M
Price To Book Value xxxxxxxxxxxxxxx0.82

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx7.7 M
Capex % of Sales xxxxxxxxxxxxxxx23.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx35 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx18 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

01/09/2023

1

Speculative Buy

$1.60

73.91%

Medical Developments International reported FY23 results broadly in line with Bell Potter's forecasts. Revenue rose 45% year on year with Penthrox sales up 54% and a 43% gain in Respiratory revenues.

The increase in Penthrox revenue was due to a combination of favourable pricing movements and volume growth across key geographical segments (Australia, Europe, Canada), the broker notes.

Respiratory revenue growth has been driven by volume growth across all regions.

Bell Potter expects FY24 to be a transitionary year as the company generates momentum targeting Emergency Departments across Australia. The lure of the US market persists with management targeting a partnership to commence its clinical program in FY25.

Target falls to $1.60 from $2.20. Speculative Buy retained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.15 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.07 cents.

MVP STOCK CHART